When compared with placebo, vunakizumab is a safe and efficacious treatment for moderate to severe plaque psoriasis among adults.

Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

A recent cohort study suggests physical activity may improve psoriasis severity and cardiovascular health, showing reduced PASI scores and better BP.

Research shows lifestyle changes like diet, exercise, and smoking cessation can assist with improving psoriasis outcomes and ...

NCT04785326), which compared the biosimilar to Stelara in patients with moderate to severe chronic plaque psoriasis. Findings showed the products were similar in pharmacokinetics, safety ...

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are ... extending its use into other chronic inflammatory diseases like ...

Skyrizi (risankizumab-rzaa) is a prescription drug that’s used to treat Crohn’s disease, plaque psoriasis ... If you have symptoms of a severe allergic reaction, such as swelling or difficulty ...

The efficacy and safety of risankizumab remains similar across racial and ethnic groups of patients with moderate to severe plaque psoriasis.

It is approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical ...